Trends in prescribinganti-obesitypharmacotherapy for paediatric weight management: Data from thePOWERWork Group

被引:17
作者
Borzutzky, Claudia [1 ,2 ]
King, Eileen [3 ,4 ]
Fox, Claudia K. [5 ]
Stratbucker, William [6 ,7 ]
Tucker, Jared [6 ,7 ]
Yee, Jennifer K. [8 ,9 ]
Kumar, Seema [10 ]
Cuda, Suzanne [11 ]
Sweeney, Brooke [12 ,13 ,14 ]
Kirk, Shelley [4 ,15 ]
机构
[1] USC, Childrens Hosp Los Angeles, Dept Pediat, Div Adolescent & Young Adult Med, Los Angeles, CA 90007 USA
[2] USC, Keck Sch Med, Los Angeles, CA 90007 USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA
[4] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[5] Univ Minnesota, Dept Pediat, Ctr Pediat Obes Med, Minneapolis, MN 55455 USA
[6] Helen DeVos Childrens Hosp, Hlth Weight Ctr, Grand Rapids, MI USA
[7] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA
[8] Harbor UCLA Med Ctr, Dept Pediat, Div Endocrinol, Torrance, CA 90509 USA
[9] Harbor UCLA, Lundquist Inst Biomed Innovat, Torrance, CA USA
[10] Mayo Clin, Dept Pediat & Adolescent Med, Div Pediat Endocrinol, Rochester, MN USA
[11] Baylor Coll Med, Childrens Hosp San Antonio, Dept Pediat, Div Adolescent Med, San Antonio, TX USA
[12] Childrens Mercy Kansas City, Gen Acad Pediat, Kansas City, MO USA
[13] Univ Missouri, Kansas City, MO 64110 USA
[14] Childrens Ctr Hlth Lifestyles & Nutr, Kansas City, MO USA
[15] Cincinnati Childrens Hosp Med Ctr, Ctr Better Hlth & Nutr, Heart Inst, Cincinnati, OH 45229 USA
来源
PEDIATRIC OBESITY | 2021年 / 16卷 / 01期
关键词
adolescent obesity; anti-obesity pharmacotherapy; paediatric obesity; paediatric weight management; weight loss medication; CHILDHOOD OBESITY; CHILDREN; ADOLESCENTS; PHARMACOTHERAPY; METFORMIN; RISKS; INTERVENTIONS; PREVENTION; REDUCTION;
D O I
10.1111/ijpo.12701
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction To better inform the field of obesity medicine, we set out to describe the current use of pharmacotherapy meant to improve patient weight status among a group of clinicians connected through the Paediatric Obesity Weight Evaluation Registry (POWER), as well as reasons behind clinicians' use or non-use of the medications. Methods Paediatric weight management (PWM) programs participating in POWER were asked to complete a program profile survey in 2014 (n = 30) and 2017 (n = 33); questions about pharmacotherapy use were included. Descriptive statistics were used to identify: (a) the proportion of PWM programs offering obesity pharmacotherapy; (b) the medications most commonly prescribed; and (c) reasons among non-prescribers for not offering pharmacotherapy. Results The 2014 and 2017 surveys were completed by 29 PWM programs (97%) and 30 PWM programs (91%), respectively. Twenty-one programs completed both surveys. In 2014, 10 (34%) programs reported offering pharmacologic agents specifically for weight control, whereas in 2017, 16 (53%) reported offering pharmacotherapy for a primary indication of weight loss. Metformin was reported as the most commonly used agent in 2014, and topiramate in 2017. Largest reported increases in use over time were for topiramate and phentermine. Discussion Our survey results demonstrate that a majority of this group of PWM programs offered pharmacotherapy to promote weight loss in patients with complications or associated medical conditions. There was a trend indicating increasing use over time, despite the significant gap regarding pharmacotherapy use in the literature. Conclusions These data suggest the need for (a) additional robust paediatric drug trials to further develop the evidence base guiding use or non-use of pharmacotherapy in paediatric weight management, and (b) increased understanding of both facilitators and barriers to prescribing anti-obesity pharmacotherapy for youth with obesity.
引用
收藏
页数:10
相关论文
共 39 条
  • [1] Administration USFaD, 2020, BELV XR LORC EIS DRU
  • [2] [Anonymous], 2019, FDA DRUG SAFETY COMM
  • [3] [Anonymous], 2012, ADIPEX P PRESCRIBING
  • [4] [Anonymous], 2010, FDA Drug Safety Communication: New Warnings for Using Gadolinium-Based Contrast Agents in Patients with Kidney Dysfunction
  • [5] Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion
    August, Gilbert P.
    Caprio, Sonia
    Fennoy, Ilene
    Freemark, Michael
    Kaufman, Francine R.
    Lustig, Robert H.
    Silverstein, Janet H.
    Speiser, Phyllis W.
    Styne, Dennis M.
    Montori, Victor M.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (12) : 4576 - 4599
  • [6] Browne Allen F, 2017, Gastrointest Endosc Clin N Am, V27, P313, DOI 10.1016/j.giec.2017.01.003
  • [7] The safety of pharmacologic treatment for pediatric obesity
    Chao, Ariana M.
    Wadden, Thomas A.
    Berkowitz, Robert I.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (04) : 379 - 385
  • [8] Childhood obesity: public-health crisis, common sense cure
    Ebbeling, CB
    Pawlak, DB
    Ludwig, DS
    [J]. LANCET, 2002, 360 (9331) : 473 - 482
  • [9] Topiramate for Weight Reduction in Adolescents With Severe Obesity
    Fox, Claudia K.
    Marlatt, Kara L.
    Rudser, Kyle D.
    Kelly, Aaron S.
    [J]. CLINICAL PEDIATRICS, 2015, 54 (01) : 19 - 24
  • [10] US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity
    Gomez, G.
    Stanford, F. C.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2018, 42 (03) : 495 - 500